When a Higher Eczema-Trial Percentage Is Not a Clear Win
LIFE IN MOTION · EVIDENCE & EVERYDAY CARE
A swimmer reading skincare and eczema headlines may notice the largest percentage first. That is understandable, but a percentage becomes meaningful only when its comparison, endpoint and uncertainty are visible. One randomized eczema-medicine trial provides a concrete example of why a numerically higher response should not automatically become a claim of proven benefit.
The primary result needs the whole comparison
In a phase 2a trial, 113 adults with moderate-to-severe atopic dermatitis received tezepelumab or placebo, both alongside topical corticosteroids. At week 12, 64.7% in the tezepelumab group and 48.2% in the placebo group achieved EASI-50, the primary response endpoint. The reported P value was 0.091, so the primary comparison was not statistically significant at a conventional 0.05 threshold. Both groups received active topical treatment. The result cannot be described as a proven additional benefit simply because 64.7 is larger than 48.2.
| Trial detail | Why it belongs beside the percentage |
|---|---|
| 113 randomized participants | The size of this phase 2a experiment. |
| Week-12 EASI-50 | A defined improvement in an eczema severity score. |
| 64.7% versus 48.2% | The two groups must be reported together. |
| P = 0.091 | The primary comparison did not meet the conventional threshold. |
Read any efficacy headline with four questions
First ask who was studied and whether they resemble the people addressed by the headline. Next identify what changed: a rash score, itch, quality of life or instrument-measured hydration. Then look for the comparison group and any treatment both groups received. Finally, read the uncertainty and whether the result was the planned primary analysis. A later exploratory result can generate a new question without reversing the status of the original primary outcome. Apply this discipline to medicine and cosmetic claims alike, while recognizing that their endpoints and regulatory roles differ. A small study can be informative without supporting a sweeping promise.
- Keep the comparator in the same sentence as the response rate.
- Distinguish EASI-50 from itch relief or complete clearance.
- Check the stated time point and whether the analysis was planned.
- Discuss treatment choices with your clinician rather than selecting from a headline.
Does a nonsignificant result prove there is no possible effect?
No. It means this analysis did not establish the claimed comparison at the chosen threshold; uncertainty, study size and design still matter.
When reading about Dr. Arsy #003, ask for the exact moisturizer endpoint, population and time point too. This medicine trial did not study #003 and provides no evidence of its efficacy.
Explore Dr. Arsy Hydration Recovery Moisturizer #003, 4 ozContinue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- What Does EASI-75 Mean in an Eczema Study?
More from this evidence series:
- Fitting Eczema Phototherapy Around Work: Questions Before You Commit
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
Sources and evidence
Prepared by the Dr. Arsy editorial team. Sources checked November 8, 2026. Educational content supports a care conversation and does not diagnose an individual. Campaign image is an AI-created editorial illustration; it is not a patient photograph or clinical outcome.